retatrutide phase 2 trial obesity nejm 2023 in adults with over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 Among participants 4 to 66

The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022

Eur Med J (2015) 3(1):5765

Health Canada is likely to approve it closer to 2028

The race to generics and alternatives Novo Nordisks first GLP-1 drug liraglutide will be off patent in November and in June Teva Pharmaceuticals received US authorisation to market the first-ever generic version, to treat diabetes

Eli Lilly, the company developing it, moved it into Phase 3 after Phase 2 results came back in 2023 showing weight loss numbers that surprised a lot of researchers

Or your provider may require you to show evidence that other strategies have failed first (e.g